---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-24-000141"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T14:53:18.574150+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MacroGenics discontinues vobra duo dosing in TAMARACK Phase 2 mCRPC study on IDMC safety recommendation

## Summary
- IDMC recommended stopping dosing for remaining participants; most had received 8-12 cycles.
- Emerging adverse events from prolonged exposure cited; participants continue safety and survival follow-up.
- Primary endpoint 6-month rPFS data to be presented at ESMO Congress September 2024.
- Company will not hold Q2 2024 earnings call; financial results release expected August 6.
- Investor conference call planned after ESMO presentation to discuss next steps for vobra duo.

## SEC filing metadata
- accession: 0001125345-24-000141
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000141/0001125345-24-000141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000141/mgnx-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-24-000141
- JSON: https://secwatch.observer/filing/0001125345-24-000141.json
- Plain text: https://secwatch.observer/filing/0001125345-24-000141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.